| 000 | 02494 a2200361 4500 | ||
|---|---|---|---|
| 001 | 1315357453 | ||
| 005 | 20250317111609.0 | ||
| 008 | 250312042018xx eng | ||
| 020 | _a9781315357454 | ||
| 037 |
_bTaylor & Francis _cGBP 37.99 _fBB |
||
| 040 | _a01 | ||
| 041 | _aeng | ||
| 072 | 7 |
_aPS _2thema |
|
| 072 | 7 |
_aTDCW _2thema |
|
| 072 | 7 |
_aMQP _2thema |
|
| 072 | 7 |
_aKJVN _2thema |
|
| 072 | 7 |
_aMBP _2thema |
|
| 072 | 7 |
_aPS _2bic |
|
| 072 | 7 |
_aTDCW _2bic |
|
| 072 | 7 |
_aMQP _2bic |
|
| 072 | 7 |
_aKJVN _2bic |
|
| 072 | 7 |
_aMBP _2bic |
|
| 072 | 7 |
_aMED000000 _2bisac |
|
| 072 | 7 |
_a338.436151094 _2bisac |
|
| 100 | 1 | _aMartina Garau | |
| 245 | 1 | 0 |
_aEuropean Medicines Pricing and Reimbursement _bNow and the Future |
| 250 | _a1 | ||
| 260 |
_bCRC Press _c20180419 |
||
| 300 | _a136 p | ||
| 520 | _bThis book is published in association with the Office of Health Economics. This book is a vital, non-technical guide illuminating recent developments within the five major European pharmaceutical markets. It clearly explains pharmaceutical regulatory policies on pricing and reimbursement, and their effects. Each chapter gives an overview of the current market, including aims, effectiveness, local markets, frameworks and politics, and then offers predictions for the next decade. Pharmaceutical executives with interests in marketing, market access and pricing will find this guide invaluable, as will health economists, government advisors and public affairs consultants. Public policy makers in areas such as the Department of Health and The Treasury and senior health service managers in hospitals will find it enlightening. It is also highly relevant to policy shapers in academia and the media, and undergraduate and postgraduate students of health economics, health policy, pharmaceutical economics and healthcare management. "This book aims not only to understand and discuss the mix of regulatory measures introduced by national policy makers in order to achieve their goals, but also to ascertain how these policies have actually shaped and influenced the characteristics and functioning of national pharmaceutical markets. In particular, each author has provided an analysis of existing pricing and reimbursement arrangements operating in their own country and an outline of policy scenarios that might emerge in the next decade." - Martina Garau and Jorge Mestre-Ferrandiz, in the Introduction. | ||
| 700 | 1 |
_aJorge Mestre-Ferrandiz _4A01 |
|
| 700 | 1 |
_aMichael Loh _4A01 |
|
| 999 |
_c4751 _d4751 |
||